Efficacy of various hemostatic agents in relieving post-extraction pain in warfarin patients

Efficacy of topical tranexamic acid soaked absorbable Gelfoam in relieving post-extraction pain in warfarin patients: A randomized, triple-blinded, multicenter, split-mouth, active-controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN71901901

Enrollment

Registered

2023-12-29

Start date

2023-01-13

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relieving postoperative pain following simple extraction of mandibular teeth in warfarin patients Oral Health

Interventions

This was a randomized, triple-blinded, multicenter, split-mouth, active-controlled clinical trial. Based on the inclusion criteria, 30 patients were recruited. 60 bilateral mandibular teeth which were

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients taking warfarin. 2. International Normalized Ratio (INR) ranges between 2.0 to 3.5. 3. Patients aged 45-70 years. 4. Patients requiring bilateral simple extraction of mandibular teeth.

Exclusion criteria

Exclusion criteria: 1. Smoking patients. 2. Patients with coagulopathies. 3. Patients with uncontrolled diabetes mellitus. 4. Patients are allergic to any anesthetic agent. 5. Patients with temporomandibular joint disorders.

Design outcomes

Primary

Measure	Time frame
The intensity of pain was evaluated on the 1st (t1), 2nd (t2), 3rd (t3), 4th (t4), 5th (t5), 6th (t6), and 7th (t7) day following extraction and hemostatic agents application using Visual Analogue Scale (VAS)	—

Secondary

Measure	Time frame
There are no secondary outcome measures.	—

Countries

Syria

Contacts

Public ContactMawia Karkoutly

mawia95.karkoutly@damascusuniversity.edu.sy+963 992647528

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 5, 2026